Ravi Ramessur, Nick Dand, Sinéad M Langan, Jake Saklatvala, Marie-Christine Fritzsche, Suzi Holland, Bernd W M Arents, Helen McAteer, Andrew Proctor, David McMahon, Michelle Greenwood, Alena M Buyx, Tamara Messer, Nina Weiler, Alexandra Hicks, Peter Hecht, Stephan Weidinger, Matladi N Ndlovu, Dai Chengliang, Matthias Hübenthal, Alexander Egeberg, Lavinia Paternoster, Lone Skov, Elke M G J De Jong, Maritza A Middelkamp-Hup, Satveer K Mahil, Jonathan N Barker, Carsten Flohr, Sara J Brown, Catherine H Smith
More severe atopic dermatitis (AD) and psoriasis are associated with a higher cumulative impact on quality of life, multimorbidity and healthcare costs. Proactive, early intervention in those most at risk of severe disease may reduce this cumulative burden and modify the disease trajectory to limit progression. The lack of reliable biomarkers for this at-risk group represents a barrier to such a paradigm shift in practice. To expedite discovery and validation, the BIOMAP consortium (Biomarkers in AD and Psoriasis, a large-scale European, inter-disciplinary research initiative) has curated clinical and molecular data across diverse study designs and sources including cross-sectional and cohort studies (small scale through to large multi-centre registries), clinical trials, electronic health records and large-scale population-based biobanks...
February 29, 2024: British Journal of Dermatology